OFFICIAL PUBLICATION OF

by its subsidiary APPco

Research roundup

Debbie Rigby 03/11/2026

Debbie Rigby rounds up the latest research news Comparative cardiorenal efficacy and safety of SGLT2 inhibitors and finerenone in chronic kidney disease with type 2 diabetes SGLT2 inhibitors and finerenone both provide cardiorenal protection and appear complementary rather than interchangeable. Both classes reduced kidney function progression and heart-failure hospitalisation. SGLT2 inhibitors were favoured for kidney

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Full scope doesn’t mean free scope’: Union

This is the government's sneaky way of cutting costs for healthcare, make the pharmacists do some of the doctors work…

Lara Armellin

Rising asthma deaths prompt best practice reminder

I believe we need stronger communucation channels to educate disinterested pharmacists regarding changes to best practice. The pharmacists I work…

Alex Jones

Allowing clozapine access ‘closer to home’

Great to see people focusing on making clozapine safely accessible. Ideally they would consider remunerating pharmacists for the task of…

Nick Logan

‘Full scope doesn’t mean free scope’: Union

Surely the patient can be expected to pay something too? How else can this be viable? I am astonished that…

Michael Khoo

Research roundup

Previous A stronger approach to bone health

This is the most recent story.

dRx series: Deprescribing ophthalmic corticosteroids in older people

Oral health series: understanding dental pain

dRx series: deprescribing COPD medicines in older people

Oral Health Series: Oral health and chronic disease

MENU

Previous A stronger approach to bone health

This is the most recent story.

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.